Current Laboratory Projects

Pipetting equipment
  • Generating novel antibodies targeting AML-associated antigen and developing therapeutics based on these antibodies
  • Developing of innovative strategies to overcome the limitations of bispecific antibodies and improve AML immunotherapy
  • Developing genome editing-based genomic approach to improve safety of AML therapies
  • Overcoming checkpoint inhibition as an approach to combinatorial therapy for AML
  • Developing rational strategies to improve AML therapy with gemtuzumab ozogamicin and other antibody-drug conjugates
  • Developing new approaches to radioimmunotherapy of AML
  • Improving adoptive cell therapy for AML with chimeric antigen receptor (CAR)-modified immune effector cells
  • Exploring the value of natural killer (NK)-cell based immunotherapy for AML
  • Using genome-scale CRISPR/Cas9 knockout screes to develop rational combination therapies that overcome AML cell resistance to                        antibody-based therapeutics